toripalimab
coherus,junshi biosciences
['toripalimab']
peri-op toripalimab (pd-1 inhibitor) plus chemo vs chemo alone demonstrated higher tumour regression in a randomised &lt;phase 2&gt; trial
good conclusion that this supports exploration in a &lt;phase 3&gt; trial which should measure an outcome that matters to patients #asco23
Dad/hubby|PhD|Med onc@Nepean|@MOGA_ORG Chair|USyd Lecturer|Interests: GI/lung cancer|value|decision making|fin tox|Luv the Rabbitohs & Dr Who|Opinions = mine